Neuland Laboratories Ltd. (IN:NEULANDLAB)
:NEULANDLAB
NEULANDLAB Stock Chart & Stats
₹15265.60
₹591.15(4.14%)
At close: 4:00 PM EST
₹15265.60
₹591.15(4.14%)
Day’s Range― - ―
52-Week Range₹10,598.05 - ₹19,748.40
Previous CloseN/A
Volume58.52K
Average Volume (3M)2.41K
Market Cap
₹180.27B
Enterprise Value₹182.56B
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹2.65B
Price to Earnings (P/E)120.0
Beta0.89
Next Earnings
May 12, 2026EPS Estimate
75.16Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)37.00
Shares Outstanding12,829,889
10 Day Avg. Volume1,318
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio-4.25
Price to Book (P/B)9.66
Price to Sales (P/S)10.27
P/FCF Ratio132.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)379.44
Revenue Forecast (FY)₹22.52B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthNeuland's robust balance sheet and high equity ratio provide durable financial flexibility to fund capacity expansion, regulatory compliance and long-term CMS contracts. Strong equity cushions downturns, supports supplier/customer confidence and lowers refinancing risk over time.
Sustained Revenue GrowthConsistent top-line expansion and the notable step-up through 2024 indicate expanding API demand and successful commercialization. Durable revenue growth improves scale economics, supports margin sustainability, and underpins long-term customer relationships in GDS and CMS businesses.
Operating Cash GenerationReliable operating cash flow and multi-year improvement in free cash flow (despite a recent dip) show the company can convert earnings into cash to fund working capital, capex and project needs. This reduces dependency on external financing and supports durable service commitments.
Bears Say
EPS Decline / VolatilityA sharp EPS contraction of roughly -40% signals volatile net profitability. Persistent EPS weakness can erode retained earnings and limit reinvestment into capacity or R&D, reducing the firm's ability to sustain long-term earnings growth and withstand industry cycles.
Free Cash Flow VariabilityObserved FCF volatility and a 2025 decline highlight risk in cash conversion. Ongoing variability can constrain capital spending, limit funding for scale-up projects, increase reliance on short-term financing for CMS contracts, and impair flexibility during demand slowdowns.
Rising Total DebtAn upward trend in total debt, even with current healthy metrics, raises leverage risk if margins or cash flow weaken. Increased debt can raise interest and refinancing burdens, reduce strategic optionality for investments or M&A, and amplify downside under regulatory or demand stress.
Neuland Laboratories Ltd. News
NEULANDLAB FAQ
What was Neuland Laboratories Ltd.’s price range in the past 12 months?
Neuland Laboratories Ltd. lowest stock price was ₹10598.05 and its highest was ₹19748.40 in the past 12 months.
What is Neuland Laboratories Ltd.’s market cap?
Neuland Laboratories Ltd.’s market cap is ₹180.27B.
When is Neuland Laboratories Ltd.’s upcoming earnings report date?
Neuland Laboratories Ltd.’s upcoming earnings report date is May 12, 2026 which is in 33 days.
How were Neuland Laboratories Ltd.’s earnings last quarter?
Neuland Laboratories Ltd. released its earnings results on Feb 09, 2026. The company reported ₹37 earnings per share for the quarter, missing the consensus estimate of ₹56.52 by -₹19.52.
Is Neuland Laboratories Ltd. overvalued?
According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued.
Does Neuland Laboratories Ltd. pay dividends?
Neuland Laboratories Ltd. pays a Annually dividend of ₹12 which represents an annual dividend yield of 0.08%. See more information on Neuland Laboratories Ltd. dividends here
What is Neuland Laboratories Ltd.’s EPS estimate?
Neuland Laboratories Ltd.’s EPS estimate is 75.16.
How many shares outstanding does Neuland Laboratories Ltd. have?
Neuland Laboratories Ltd. has 12,829,889 shares outstanding.
What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?
Neuland Laboratories Ltd. reported an EPS of ₹37 in its last earnings report, missing expectations of ₹56.52. Following the earnings report the stock price went up 6.856%.
Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:NEULANDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuland Laboratories Ltd.
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.
Technical Analysis
Caplin Point Laboratories Limited
―
―
Granules India Limited
―
Marksans Pharma Limited
―
NATCO Pharma Limited
―